Citalopram Reduces Agitation in Patients With Alzheimer's Citalopram Reduces Agitation in Patients With Alzheimer's

Results of the CitAD trial show 30 mg daily moderates agitation in AD but also affects cognition, can cause electrocardiography changes, and is no longer recommended in older adults. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news